Takeda Pharmaceutical (TAK) Competitors

Pfizer (NYSE:PFE) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk.

Does the MarketBeat Community prefer PFE or TAK?

Pfizer received 1389 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 69.06% of users gave Pfizer an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Pfizer	Outperform Votes 1489 69.06%	Underperform Votes 667 30.94%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Does the media prefer PFE or TAK?

In the previous week, Pfizer had 25 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 28 mentions for Pfizer and 3 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 0.73 beat Takeda Pharmaceutical's score of 0.64 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	18 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, PFE or TAK?

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of PFE or TAK?

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has better earnings and valuation, PFE or TAK?

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Pfizer is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$58.50B	2.71	$2.12B	-$0.06	-466.59
Takeda Pharmaceutical	$28.20B	1.51	$994.06M	$0.55	24.44

Do analysts rate PFE or TAK?

Pfizer presently has a consensus target price of $35.86, indicating a potential upside of 25.46%. Takeda Pharmaceutical has a consensus target price of $14.00, indicating a potential upside of 4.17%. Given Takeda Pharmaceutical's higher probable upside, equities analysts clearly believe Pfizer is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is PFE or TAK more profitable?

Takeda Pharmaceutical has a net margin of 6.18% compared to Takeda Pharmaceutical's net margin of -0.56%. Pfizer's return on equity of 9.92% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	-0.56%	8.64%	3.70%
Takeda Pharmaceutical	6.18%	9.92%	4.71%

Is PFE or TAK a better dividend stock?

Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 6.0%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.9%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 47.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Pfizer beats Takeda Pharmaceutical on 14 of the 20 factors compared between the two stocks.